![Yasir Al-Wakeel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Yasir Al-Wakeel
Directeur/Membre du Conseil chez
MAXCYTE, INC.
Fortune : 98 008 $ au 31/05/2026
Profil
Yasir Baha Al-Wakeel is CEO-Partner at Flagship Pioneering, Inc. since 2025.
Dr. Al-Wakeel is Chief Executive Officer at Vesalius Therapeutics, Inc. since 2025.
Dr. Al-Wakeel is Independent Non-Executive Director at MaxCyte, Inc. since 2021.
Dr. Al-Wakeel is Director at Vicore Pharma Holding AB since 2024.
Former roles include Chief Executive Officer at Addition Therapeutics, Inc., Treasurer, Chief Financial & Accounting Officer at Merrimack Pharmaceuticals, Inc. in 2017, Research Analyst at Credit Suisse Securities (Europe) Ltd. from 2008 to 2015, Chief Financial Officer at BioNTech US, Inc. from 2017 to 2020, and CFO, CAO & Head-Corporate Development at Kronos Bio, Inc. from 2020 to 2023.
Education includes a doctorate from the University of Oxford in 2005 and a graduate degree from the University of Cambridge in 2001.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MAXCYTE, INC. 0,08% | 17/06/2026 | 80 998 ( 0,08% ) | 98 008 $ | 31/05/2026 |
Postes actifs de Yasir Al-Wakeel
| Sociétés | Poste | Début |
|---|---|---|
| MAXCYTE, INC. | Directeur/Membre du Conseil | 15/06/2021 |
| VICORE PHARMA HOLDING AB | Directeur/Membre du Conseil | 07/05/2024 |
Flagship Pioneering, Inc.
 Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Private Equity Investor | 01/09/2025 |
Vesalius Therapeutics
 Vesalius Therapeutics BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for common human diseases | Directeur Général | 16/09/2025 |
Anciens postes connus de Yasir Al-Wakeel
| Sociétés | Poste | Fin |
|---|---|---|
| KRONOS BIO, INC. | Directeur Financier/CFO | 15/09/2023 |
| NEON THERAPEUTICS, INC. | Directeur Financier/CFO | 01/05/2020 |
| MERRIMACK PHARMACEUTICALS | Directeur Financier/CFO | 01/07/2017 |
Credit Suisse Securities (Europe) Ltd.
 Credit Suisse Securities (Europe) Ltd. Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 01/06/2015 |
Formation de Yasir Al-Wakeel
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
97
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
MaxCyte, Inc.
 MaxCyte, Inc. BiotechnologyHealth Technology Specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of therapeutic products | Health Technology |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merrimack Pharmaceuticals, Inc.
 Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes drugs for the treatment of immunological & autoimmune diseases and cancer | Health Technology |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Flagship Pioneering, Inc.
Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Finance |
Credit Suisse Securities (Europe) Ltd.
Credit Suisse Securities (Europe) Ltd. Investment Banks/BrokersFinance Provides brokerage services | Finance |
Vicore Pharma Holding AB
 Vicore Pharma Holding AB Pharmaceuticals: MajorHealth Technology Engages in research and development of drugs for lung diseases | Health Technology |
BioNTech US, Inc.
 BioNTech US, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immunotherapies for cancer | Health Technology |
Kronos Bio, Inc.
 Kronos Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | Health Technology |
Vesalius Therapeutics
Vesalius Therapeutics BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for common human diseases | Health Technology |
